^
Association details:
Biomarker:KIT D820Y
Cancer:Melanoma
Drug:sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas

Excerpt:
Finally, we found significant growth suppressive effects of sunitinib in two acral melanoma cell lines; one harboring the D820Y mutation and one showing SCF-dependent KIT activation.
DOI:
10.1002/ijc.24048